Jordan Sterilizers and Detergents Import Directives: Device Channel and Traceability Duties

1. Key takeaways

Jordan has written sterilizers and detergents into the very title of its medical device importation directives — this is not an ancillary clause but an expressly stated scope of application. GRZAN’s conclusion is that products directed at healthcare institutions and used for the sterilisation of medical devices or surfaces take the device channel in Jordan, and are not treated as cosmetics or general chemicals.

The second conclusion is that Jordan imposes flow-tracing obligations on sterilants, detergents and filler injection products. JFDA has required the relevant importers to retain, for every imported batch, the import invoice and the sales record, itemising each sale counterparty, so as to ensure that users are authorised institutions.

The third conclusion is that in 2025 Jordan updated the testing, compliance and market control requirements for medical products, sterilants, detergents and cosmetics. Companies already licensed in Jordan must re-check whether their current testing items still meet the requirements; companies not yet licensed must prepare their documents against the updated requirements.

• Sterilizers and detergents are named in the directive title itself, so the device channel applies expressly.
• Import invoices and sales records must be retained batch by batch for sterilants, detergents and filler injections.
• The 2025 update tightened both testing and market control requirements at the same time.
• Companies should run a gap analysis of existing certificates against the updated testing items.

For channel planning, the combined effect of these conclusions is that sterilants and detergents behave like regulated devices in every practical sense: they enter through the device channel, carry flow-tracing duties, and sit inside the 2025 testing and market control update. A distribution arrangement that anticipates all three layers will survive an inspection; one that treats the products as simple consumables will not.

2. Legal basis

The channel and its obligations rest on the following instruments.

Provision numbers are subject to the Arabic original texts issued in the Jordanian Official Gazette and by JFDA.

3. Expert insights

Insight 1: the sterilisation purpose in the definition is the legal foundation. Jordan’s definition of a medical device lists “sterilisation of medical devices, surfaces and surgical instrument sets” as one of the six intended purposes, so sterilants and detergents fall naturally within the device category. A cosmetics-route submission will be returned at formal screening, and re-routing through the device channel usually costs two to three months. The cost is not only time: a returned submission also consumes goodwill at the screening stage and forces the sales calendar to be rebuilt around a new approval date.

Insight 2: flow tracing is Jordan’s characteristic control over high-risk consumables. Compared with batch management for ordinary devices, Jordan requires sterilants, detergents and filler injection products to be “traceable transaction by transaction to the final user”. GRZAN recommends allocating in the distributor agreement the obligations of compiling, retaining and submitting sales records clearly to the Jordanian side, together with agreed liability for non-performance.

Insight 3: the 2025 update tightened testing and market control simultaneously. In 2025 Jordan updated the testing, compliance and market control requirements for medical products, sterilants, detergents and cosmetics. The update covers both “testing” (the pre-market technical gate) and “market control” (the intensity of post-market surveillance). Such simultaneous tightening is usually accompanied by a rise in on-site inspection frequency.

Insight 4: the transfer of agency rights for cosmetics and cosmeceuticals has its own threshold. JFDA requires manufacturers and importers of cosmetics and cosmeceuticals to submit a bank-signed and certified waiver when applying to transfer agency rights. Although this belongs to the cosmetics line, cosmeceuticals and device-use disinfection products often overlap in the distribution channel, so companies adjusting their Jordan channel should check both lines at once. A channel adjustment that ignores the cosmetics-side waiver rules can leave disinfection products stranded between two regimes at exactly the wrong moment.

4. Practical recommendations

• Determine the intended use first, then the channel. Products used to sterilise medical devices or medical surfaces take the device channel; products used to cleanse human skin may fall into the cosmetics channel; where both apply, confirm the specific intended use with JFDA in writing.
• Write the sales-record obligation into the agreements. Require the Jordanian side to establish and keep sales records batch by batch, with clear retention periods and availability for inspection.
• Re-check existing certificates against the testing items as updated in 2025. For licensed products, run a gap analysis once to confirm whether additional testing is needed.
• Map each product to its channel and its record-keeping duties before signing any distribution agreement, so that obligations are priced and allocated from the start.

5. Verification checklist

• □ Confirm whether the product’s intended use falls within the sterilisation purpose clause of the device definition
• □ Confirm the submission channel is the device channel, not the cosmetics or chemical channel
• □ Confirm the import-side documentation names the products as devices, so that customs and JFDA records describe the same goods consistently
• □ Confirm whether the product is a filler injection subject to the transaction-by-transaction sales-record duty
• □ Check whether the 2025 update on testing and market control requirements added any testing item
• □ Stipulate in the agreements the compiling, retention and submission duties for sales records
• □ Re-verify the cited provision numbers against the Arabic original texts of the Official Gazette

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages Jordan Food and Drug Administration (JFDA) registrations, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com